Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has successfully raised £340,000 through a share placing, with the funds earmarked for advancing clinical trials of its lead product, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia. This financial move strengthens the company’s efforts in clinical development, potentially enhancing its position within the biopharmaceutical industry and offering promising implications for stakeholders as the trials progress.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals, a publicly traded company listed on the London Stock Exchange, is a clinical-stage biopharmaceutical group. It focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging bone marrow transplantation technology to address incurable life-threatening conditions. The company operates from its headquarters in London and has subsidiaries in New York City.
YTD Price Performance: -1.23%
Average Trading Volume: 32,027
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £14.19M
See more data about HEMO stock on TipRanks’ Stock Analysis page.
